Welcome to our dedicated page for Clarivate news (Ticker: CLVT), a resource for investors and traders seeking the latest updates and insights on Clarivate stock.
Clarivate Plc reports developments in data, analytics and workflow software for academia and government, intellectual property, and life sciences and healthcare. Its news commonly covers earnings, subscription and recurring revenue trends, cash flow and leverage actions, and progress under its operating improvement initiatives.
Company updates also focus on AI-enabled research and decision-support products, including Web of Science Research Intelligence, Nexus Connect, Cortellis Regulatory Intelligence, Derwent-based patent analytics and other Clarivate data assets. Recurring announcements address institutional research intelligence, academic library workflows, regulatory intelligence for life sciences teams, intellectual property benchmarks and investor conference appearances.
Clarivate (NYSE:CLVT) launched Web of Science Research Intelligence on May 6, 2026, an AI-native research intelligence platform now available globally to institutions.
The platform unifies publications, patents, funding, policy documents and clinical trials with publisher-neutral Web of Science Core Collection data, embeds responsible academic AI, and was shaped with more than 50 development partners across 20 countries to support funding, collaboration, strategy and societal impact reporting.
Clarivate (NYSE: CLVT) reported Q1 2026 results with revenues of $585.5M and Adjusted EBITDA of $241.2M. Adjusted net income rose to $119.3M and adjusted EPS to $0.18. The company generated $78.9M free cash flow and used cash to retire $143.1M of debt. Clarivate reaffirmed full‑year 2026 guidance, including $2.30B–$2.42B revenues, $980M–$1.04B Adjusted EBITDA, and $365M–$435M free cash flow.
Clarivate (NYSE: CLVT) launched Nexus Connect on April 28, 2026, an institutional AI gateway that embeds university‑branded access to licensed library resources and services inside general-purpose AI chat agents via the Model Context Protocol (MCP).
Core features include entitlement-based access, institutional identity, configurable scope, extensible architecture, and enterprise-grade security; an early access program begins July 2026 with five initial universities in North America and APAC.
Clarivate (NYSE: CLVT) will report first quarter 2026 results before the market opens on Wednesday, April 29, 2026. The company will publish a press release and earnings supplement with financial information on its investor website.
Clarivate will host a live conference call and webcast at 9:30 AM ET on April 29, 2026, with replay available on the investor site two hours after the call and remaining online for one year.
Clarivate (NYSE:CLVT) launched the inaugural Clarivate AI50, a data-driven benchmark naming 50 leading organizations (52 due to a tie) for high-strength AI inventions on March 26, 2026. The list is drawn from the Derwent World Patents Index using Clarivate's Derwent Strength Index and invention-level scoring.
Key findings: ~80% of AI50 are headquartered in Mainland China (15), the United States (14), South Korea (6) and Japan (6); top 0.5% of AI patents selected; inventions retained require patent family members in at least two countries.
Clarivate (NYSE: CLVT) announced on March 10, 2026 that Cortellis Regulatory Intelligence (CRI) will integrate with Anthropic's Claude via the open Model Context Protocol (MCP).
This integration embeds authoritative regulatory content into Claude workflows, giving life sciences teams access to referenced regulatory answers and enabling CRI to work alongside internal data and agents.
Clarivate (NYSE: CLVT) announced that Jonathan Collins, Executive Vice President and Chief Financial Officer, will present at the Wolfe Research FinTech Forum on March 10, 2026 at 10:55 AM ET.
The presentation will be webcast live with a replay available on the company's investor site and the event platform, remaining accessible for 90 days.
Clarivate (NYSE: CLVT) reported fourth-quarter and full-year 2025 results, highlighting improved cash generation and a shift to subscription revenue. Total 2025 revenue was $2,455.2M, organic ACV rose 1.8%, and free cash flow reached $365.3M. The company is pursuing a sale of its Life Sciences & Healthcare business and provided 2026 guidance projecting organic ACV 2.0–3.0% and Adjusted EBITDA $980M–$1.04B.
The company returned ~$225M to shareholders via buybacks and reduced debt through accelerated repayments, while forecasting stronger margins and ~10% free cash flow growth in 2026.
Clarivate (NYSE: CLVT) released a video webinar, Intelligence Amplified in the Age of AI, on February 3, 2026, explaining how its proprietary data and AI capabilities support research, IP, and life sciences workflows. The session details AI Research Assistants, AI Workflow Agents, and AI Ecosystem Access.
The webinar emphasizes 97% revenue from proprietary solutions and how curated, structured data reduces hallucination risks in high‑stakes decisions.
Clarivate (NYSE: CLVT) announced that subsidiary Camelot Finance S.A. fully redeemed the remaining $100 million aggregate principal of its 4.50% senior secured notes due 2026 on Jan 30, 2026, paying 100% of principal plus accrued interest.
The redemption was funded with cash on hand and is part of Clarivate's capital allocation strategy, which also included repurchasing ~56 million ordinary shares for $225 million in 2025 (including ~21 million shares for $75 million in Q4 2025).